Abstract

Platinum-based anticancer drugs are one of the most widely used drug classes in cancer therapy. Almost half of the chemotherapy regimens used today contains a platinum drug, such as cisplatin or carboplatin. However, the drug resistance and non-specific cytotoxicity ultimately limits broader application of these drugs. Improvement of drug targeting and delivery systems are effective approaches to mitigate these disadvantages. This review focuses on liposome and micelle-based formulations using in the delivery of platinum-based anticancer drugs in clinical trials.

Keywords: Anticancer agents, cisplatin, liposome-based formulations, micelle-based formulations